Scinai Immunotherapeutics Ltd. - American Depositary Shares (SCNI)

Secondary debt liquidity for SCNI proxies remains highly resilient despite headline noise. Watching gross margin expansion.

Option volume on SCNI indicates large block hedging by prime desks. Downside asymmetry is expanding.

Credit spreads across related paper are tightening faster than equity multiples for SCNI. High likelihood of institutional multiple re-rating if cash flows hold.

Option volume on SCNI indicates large block hedging by prime desks. Downside asymmetry is expanding.

On our desk, the valuation metrics for SCNI present a classic distressed micro-cap profile. With a market capitalization hovering between $910,000 and $1.18 million and the stock trading around $0.23 to $0.27, retail forums show a surprisingly high bullish sentiment score (100/100 on AltIndex). However, this disconnect between community optimism and a severe -85.19% trailing-twelve-month performance demands caution. We are watching how the market digests the April 2026 $2.61 million private placement and whether retail sentiment can hold up against heavy structural dilution.

From a regulatory and compliance standpoint, SCNI is facing major near-term pressures. The company received a Nasdaq minimum bid price deficiency notice on March 12, 2026, giving them until September 8, 2026, to regain compliance. To address this, management announced an aggressive ADS ratio change effective August 21, 2026, shifting from one ADS representing 4,000 ordinary shares to one ADS representing 40,000 ordinary shares. For risk managers, corporate actions of this magnitude to artificially inflate the nominal share price are significant red flags regarding underlying equity health.